Short Interest Coverage: Asterias Biotherapeutics Incorporated (NYSEMKT:AST)’s Trend Up, Especially After Decreased Shorts

November 24, 2016 - By Richard Conner   ·   0 Comments

Short Interest Coverage: Asterias Biotherapeutics Incorporated (NYSEMKT:AST)’s Trend Up, Especially After Decreased Shorts

The stock of Asterias Biotherapeutics Incorporated (NYSEMKT:AST) registered a decrease of 1.59% in short interest. AST’s total short interest was 1.57 million shares in November as published by FINRA. Its down 1.59% from 1.60M shares, reported previously. With 76,300 shares average volume, it will take short sellers 21 days to cover their AST’s short positions. The short interest to Asterias Biotherapeutics Incorporated’s float is 9.56%. The stock decreased 6.48% or $0.35 on November 23, hitting $5.05. About 465,111 shares traded hands or 162.36% up from the average. Asterias Biotherapeutics Inc (NYSEMKT:AST) has risen 19.95% since April 22, 2016 and is uptrending. It has outperformed by 14.54% the S&P500.

Asterias Biotherapeutics, Inc. is a biotechnology company. The company has a market cap of $224.06 million. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. It currently has negative earnings. The Firm has over two technology platforms.

Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage

Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was upgraded by Zacks to “Hold” on Thursday, September 3. The stock has “Outperform” rating given by FBR Capital on Thursday, November 19. The firm has “Buy” rating given on Tuesday, August 11 by MLV. Chardan Capital Markets initiated the stock with “Buy” rating in Monday, May 23 report.

AST Company Profile

Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.

More important recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: Prnewswire.com which released: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” on March 31, 2016, also Prnewswire.com published article titled: “Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury …”, Prnewswire.com published: “Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with …” on September 14, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) was released by: Prnewswire.com and their article: “Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA …” with publication date: February 24, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>